NCT05938920: Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- State
- Completed
- Phase
- Phase 2
- People
- 71 taking part
- Started
- 19 Jun 2023
- Primary completion
- 8 Aug 2024
- Arms
- INS018_055 30 mg QD, INS018_055 30 mg BID, INS018_055 60 mg QD
- Results
- Posted on the registry
- 19 Jun 2023: Trial started
- 11 Jul 2023: Trial registered
- 8 Aug 2024: Trial completed
- 2 Dec 2025: Trial results posted